Navigation Links
Medarex to Present at the Susquehanna Financial Group Healthcare Conference
Date:2/28/2008

PRINCETON, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Susquehanna Financial Group Second Annual SIGnificant Investment Options in Healthcare Conference at 3:00 p.m. ET on Wednesday, March 5, 2008, in New York. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trad
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
2. Medarex Announces Completion of Sale of Shares in Genmab A/S
3. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
4. Medarex Announces Election of Marc Rubin as New Board Member
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
7. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
8. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
9. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
10. InterMune to Present at the SIGnificant Options in Healthcare Conference
11. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Calif. , July 24, 2014 SRI ... contract with the National Institute of Allergy and Infectious ... to conduct preclinical development of potential therapies for HIV ... drugs to treat HIV and AIDS and the complications ... as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 2014 ... Sulphate Industry” is a professional and in-depth research ... introduces Potassium Sulphate basic information, including its ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... SAN DIEGO, Oct. 4 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the 28th Annual Scientific Meeting of ... the San Diego Convention Center, October 8-12, 2010.Sunday, October ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... special dividend payment of $0.50 per share to all stockholders ... record date. As previously announced, the conversion ... 15, 2012 was adjusted to 140.571 shares of common stock ...
... 1 Biotech posted its strongest monthly and quarterly performance ... September rally for equities in more than 70 years. The ... and 13 percent in the third quarter. The Dow Jones ... appreciation during what historically has been a bad month for ...
Cached Biology Technology:Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society 2Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 2Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 3Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 4
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/24/2014)... NEW YORK, NY (July 24, 2014) Scientists ... Research Institute are one step closer to creating ... from a patient,s own cells. , For ... stem (iPS) cells lines from skin samples of ... they developed an accelerated protocol to induce these ...
(Date:7/24/2014)... /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative technology ... emergency room wait times by an average of 92 ... according to a recent study published in the Academic ... the suite to access data from incoming patients, implanted ... "Using Geneva,s technology platform we have been able to ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... to develop and evaluate new tools to control the ... five year, 12 million project involving sixteen partners in ... Framework programme. Because malaria is transmitted by mosquitoes, ... Wide scale use of insecticides on bednets and ...
... has long been used as a crop fertilizer, but the ... in manure is ever present. The ratio of nitrogen to ... needs of most crops. Therefore, crops tend to be overloaded ... but the excess phosphorus from the process can damage the ...
... "The rapid translation of biologically-based laboratory discoveries into daily ... trip back from the clinic to the laboratory, to ... behavior. It is imperative for basic researchers to understand ... the knowledge and skills to integrate and use new ...
Cached Biology News:€12 million ($16.9 million) project to develop new tools for malaria control 2
Agarose Gel Loading Dye Mixture 6X...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: